Cargando…

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer

BACKGROUND: Immunotherapy is the most promising treatment in triple-negative breast cancer (TNBC), and its efficiency is largely dependent on the intra-tumoral immune cells infiltrations. Thus, novel ways to assist immunotherapy by increasing immune cell infiltrations were highly desirable. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Tao, Wang, Zhen, Liu, Jiahao, Wang, Ge, Zhou, Dongchen, Du, Yaying, Li, Xingrui, Xia, Yu, Gao, Qinglei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213695/ https://www.ncbi.nlm.nih.gov/pubmed/35756622 http://dx.doi.org/10.3389/fonc.2022.820696

Ejemplares similares

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis
por: Xu, Tao, et al.
Publicado: (2021)

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
por: Wang, Bin, et al.
Publicado: (2021)

Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers
por: Hur, Saem, et al.
Publicado: (2020)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
por: Lin, Z. Ping, et al.
Publicado: (2018)

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
por: Husinka, Lakyn, et al.
Publicado: (2020)

A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer
por: Qiu, Pengjun, et al.
Publicado: (2022)

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
por: Reese, Jordan M., et al.
Publicado: (2017)

Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study
por: Zhou, Dongchen, et al.
Publicado: (2022)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Comprehensive Analysis of Role of Cyclin-Dependent Kinases Family Members in Colorectal Cancer
por: Guan, Liping, et al.
Publicado: (2022)

Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions
por: Merlini, Alessandra, et al.
Publicado: (2023)

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack
por: Hamilton, Duane H., et al.
Publicado: (2018)

The cyclin dependent kinase inhibitor p21(Cip1/Waf1) is a therapeutic target in high-risk neuroblastoma
por: Sorteberg, Agnes Luise, et al.
Publicado: (2022)

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
por: Rottier, Pauline, et al.
Publicado: (2023)

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck
por: Seront, Emmanuel, et al.
Publicado: (2019)

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2016)

Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity of Tetrastigma hemsleyanum
por: Wei, Chaoguang, et al.
Publicado: (2022)

Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice
por: Gagliano, Ambrogio, et al.
Publicado: (2021)

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models
por: Yin, Lei, et al.
Publicado: (2022)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
por: Łukasik, Paweł, et al.
Publicado: (2021)

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy
por: Kren, Betsy T, et al.
Publicado: (2015)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Cyclin-Dependent Kinase 5 Regulatory Subunit Associated Protein 3: Potential Functions and Implications for Development and Disease
por: Sheng, Linna, et al.
Publicado: (2021)

Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing
por: Baig, Mohammad Hassan, et al.
Publicado: (2022)

Induction of Pyroptosis: A Promising Strategy for Cancer Treatment
por: Wang, Lei, et al.
Publicado: (2021)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells
por: Strnad, M., et al.
Publicado: (2001)

Purine Inhibitors of Cyclin-Dependent Kinase and Their Apoptosis and Cytotoxicity Mechanisms
por: Strnad, M., et al.
Publicado: (2001)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
por: Gao, Shan, et al.
Publicado: (2023)

Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
por: Li, Bin-Bin, et al.
Publicado: (2019)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer
por: Ionkina, Anastasia A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pumn6n59bs8f0441176ht6tqea